skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improving cancer treatment with cyclotron produced radionuclides

Abstract

Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.

Authors:
;
Publication Date:
Research Org.:
Sloan-Kettering Inst. for Cancer Research, New York, NY (United States)
Sponsoring Org.:
USDOE; USDOE, Washington, DC (United States)
OSTI Identifier:
7262966
Report Number(s):
DOE/ER/60407-6
ON: DE92040305
DOE Contract Number:  
FG02-86ER60407
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; RADIOPHARMACEUTICALS; CHEMICAL PREPARATION; URIDINE; LABELLING; CYCLOTRONS; FLUORINE 18; GALLIUM 66; IMMUNOGLOBULINS; IODINE 124; NUCLEAR MEDICINE; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; PROGRESS REPORT; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; ACCELERATORS; AZINES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; CHEMISTRY; COMPUTERIZED TOMOGRAPHY; CYCLIC ACCELERATORS; DAYS LIVING RADIOISOTOPES; DIAGNOSTIC TECHNIQUES; DOCUMENT TYPES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; GALLIUM ISOTOPES; GLOBULINS; HETEROCYCLIC COMPOUNDS; HOURS LIVING RADIOISOTOPES; HYDROXY COMPOUNDS; IMMUNOLOGY; IMMUNOTHERAPY; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MEDICINE; NANOSEC LIVING RADIOISOTOPES; NUCLEI; NUCLEOSIDES; NUCLEOTIDES; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; PROTEINS; PYRIMIDINES; RADIOIMMUNOLOGY; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; RIBOSIDES; SYNTHESIS; THERAPY; TOMOGRAPHY; URACILS; 550603* - Medicine- External Radiation in Therapy- (1980-); 400703 - Radiochemistry & Nuclear Chemistry- Radioisotope Production

Citation Formats

Larson, S.M., and Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. United States: N. p., 1992. Web. doi:10.2172/7262966.
Larson, S.M., & Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. United States. doi:10.2172/7262966.
Larson, S.M., and Finn, R.D.. Tue . "Improving cancer treatment with cyclotron produced radionuclides". United States. doi:10.2172/7262966. https://www.osti.gov/servlets/purl/7262966.
@article{osti_7262966,
title = {Improving cancer treatment with cyclotron produced radionuclides},
author = {Larson, S.M. and Finn, R.D.},
abstractNote = {Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.},
doi = {10.2172/7262966},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Aug 04 00:00:00 EDT 1992},
month = {Tue Aug 04 00:00:00 EDT 1992}
}

Technical Report:

Save / Share: